Suppr超能文献

抗凝血酶III:回顾走过的路

Antithrombin III: a backward glance o'er travel'd roads.

作者信息

Seegers W H

出版信息

Adv Exp Med Biol. 1975;52:195-215.

PMID:47704
Abstract

By devising and applying quantitative methods for the assay of thrombin and autoprothrombin C and by developing techniques for their purification, it was possible to obtain information about the function and properties of antithrombin. The inhibitor is a protein for which the initial purification steps consist of removing fibrinogen from plasma by heating to 56 degrees for 3 min, removing prothrombin complex by absorption on barium carbonate, absorbing the antithrombin on aluminum hydroxide, and eluting with phosphate buffer. Antithrombin is limited in its capacity to neutralize thrombin activity, and, under some conditions, the rate of inhibition was accelerated, but equivocal results were involved. Heparin cofactor was found to be essential for retarding the formation of thrombin, and, by inference, it is essential for retarding the formation of autoprothrombin C. Heparin cofactor and antithrombin III are the same. Thrombin absorbs on fibrin, and this has been referred to as the "antithrombin I effect." Interference with the thrombin-fibrinogen reaction by mixtures of antithrombin III and heparin is called the "antithrombin II henomenon." The acceleration of thrombin inactivation at the time thrombin forms is called the "antithrombin IV effect." It was discovered that antithrombin III neutralizes thrombin, as well as autoprothrombin C. The inhibitor and the enzyme form a mutual depletion system. To assay for antithrombin III, a standard quantity of thrombin (about 1,100U/ml) was reacted with antithrombin III for 2 hr. The percent thrombin inactivated was then measured. In random samples of human blood, a wide range of antithrombin III concentration was found. The inhibitor is relatively stable in plasma and serum. It is not changed in concentration when Dicumarol therapy is instituted. Ether extraction of plasma reduces antithrombin III activity. Seitz filtration of plasma did not remove activity. Under special conditions, antithrombin III enhances esterase activity of thrombin. Under special conditions, thrombin regenerates from the thrombin-antithrombin III complex. Antithrombin III neutralizes the activity of prethrombin-E and thrombin-E; consequently, an active histidine center found in the B1 chain of thrombin is not essential for the binding of antithrombin. Autoprothrombin II-A activity was neutralized by antithrombin III. Autoprothrombin C was found to be neutralized by antithrombin III; the amounts required varied with the molecular forms of autoprothrombin C. Thrombin and autoprothrombin C apparently occupy the same binding sites on antithrombin III. An equation was developed to account for all the known characteristics of antithrombin III functions. The kinetic aspects of thrombin neutralization were found to correspond exactly with those of autoprothrombin C. Antithrombin III is a high-capacity inhibitor of the two most powerful enzymes in blood coagulation.

摘要

通过设计并应用测定凝血酶和自身凝血酶原C的定量方法,以及开发其纯化技术,得以获取有关抗凝血酶功能和特性的信息。该抑制剂是一种蛋白质,其初步纯化步骤包括通过在56摄氏度加热3分钟从血浆中去除纤维蛋白原,通过在碳酸钡上吸附去除凝血酶原复合物,在氢氧化铝上吸附抗凝血酶,并用磷酸盐缓冲液洗脱。抗凝血酶中和凝血酶活性的能力有限,在某些条件下,抑制速率会加快,但结果并不明确。发现肝素辅因子对于延缓凝血酶的形成至关重要,据此推断,它对于延缓自身凝血酶原C的形成也至关重要。肝素辅因子和抗凝血酶III是相同的。凝血酶吸附在纤维蛋白上,这被称为“抗凝血酶I效应”。抗凝血酶III和肝素混合物对凝血酶-纤维蛋白原反应的干扰被称为“抗凝血酶II现象”。在凝血酶形成时凝血酶失活的加速被称为“抗凝血酶IV效应”。发现抗凝血酶III能中和凝血酶以及自身凝血酶原C。抑制剂和酶形成一个相互消耗的系统。为了测定抗凝血酶III,将标准量的凝血酶(约1100U/ml)与抗凝血酶III反应2小时。然后测量失活的凝血酶百分比。在人类血液的随机样本中,发现抗凝血酶III浓度范围很广。该抑制剂在血浆和血清中相对稳定。开始双香豆素治疗时其浓度不变。血浆的乙醚萃取会降低抗凝血酶III的活性。血浆的Seitz过滤不会去除活性。在特殊条件下,抗凝血酶III会增强凝血酶的酯酶活性。在特殊条件下,凝血酶可从凝血酶-抗凝血酶III复合物中再生。抗凝血酶III中和前凝血酶-E和凝血酶-E的活性;因此,在凝血酶B1链中发现的活性组氨酸中心对于抗凝血酶的结合并非必需。自身凝血酶原II-A的活性被抗凝血酶III中和。发现自身凝血酶原C被抗凝血酶III中和;所需量随自身凝血酶原C的分子形式而变化。凝血酶和自身凝血酶原C显然占据抗凝血酶III上相同的结合位点。开发了一个方程来解释抗凝血酶III功能的所有已知特征。发现凝血酶中和的动力学方面与自身凝血酶原C的完全一致。抗凝血酶III是血液凝固中两种最强大酶的高容量抑制剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验